Press

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”), a developer of naturally derived psilocybin-based therapeutics, today announced that the first site initiation visit has been successfully completed at the first Australian clinical trial site for the Company’s Phase IIb study of nature derived (non-synthetic) psilocybin…

Vancouver, British Columbia–(Newsfile Corp. – September 9, 2024) – Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE: 4DO), a leader in comprehensive mental health and wellness care, is excited to announce a research and patient care partnership with Sama Therapeutics for expanding access through novel technology. This collaboration marks the release of an advanced, proprietary…

Vancouver, Canada, Sept. 06, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (“PCT”) for its…

Toronto, Ontario–(Newsfile Corp. – September 10, 2024) – Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) (“Braxia Scientific”, or the “Company”) announced today that an annual general and special meeting (the “Meeting”) of the common shareholders will be held in person at 10:00 a.m. (Toronto time) on Wednesday October 9, 2024, at 1430…